Frank McLaughlin
Frank’s practice focuses on the defence of pharmaceutical product liability class actions, medical malpractice claims and a range of commercial litigation cases. Frank is a leading trial lawyer in medical malpractice litigation, having successfully defended over 30 cases through trial, both jury and non-jury. Frank has many high-profile representative works, including acting as National lead counsel for a number of pharmaceutical innovator companies. Frank and his team have taken creative approaches to the defence of class actions and have defeated class certification motions on behalf of AstraZeneca, in Martin v. AstraZeneca (involving the atypical anti-psychotic medication Seroquel), and on behalf of Lundbeck in Price v. Lundbeck (involving the anti-depressant Celexa)(currently under appeal). Frank has been involved in many leading medical malpractice decisions and specializes in birth injury litigation. Frank is a frequent presenter at conferences on medical legal issues. · McCarthy Tétrault
About
Frank McLaughlin is a trial lawyer at McCarthy Tétrault in Canada who focuses on defending pharmaceutical product liability class actions, medical malpractice (including birth injury) claims and a range of commercial litigation matters. He has successfully defended over 30 cases through trial (jury and non-jury), has acted as national lead counsel for several pharmaceutical innovator companies, and has defeated class certification motions in notable matters such as Martin v. AstraZeneca and Price v. Lundbeck.